MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Medical Devices & Technology (Technology)
*Driving Forces: Telemedicine,Telehealth, Mobile Health, mHealth, Virtual, Digital Health, DTx (Digital Therapeutics)
*Driving Forces: Telemedicine,Telehealth, mHealth & Home Health (Sectors)
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
*Pioneers: Cardiology & Cardiovascular
Medical & Clinical Specialities
Diseases, Illnesses, Injury & Injuries
HIV/AIDS
Attachments
wikipedia
Parents
Diseases, Illnesses, Injury & Injuries
Infectious Disease
Medical & Clinical Specialities
MedTechIQ Market Sectors
Children
*Funding: HIV/AIDS & STD (Archives 2017)
*Funding: HIV/AIDS & STD (Archives 2018-2019)
*Funding: HIV/AIDS & STD (Sexually Transmitted Disease)
*Key People: HIV/AIDS
2018: CDC-RFA-PS20-2005 _ Medical Monitoring Project (MMP)
2019: SAMHSA_TI-19-008 _Minority Aids Initiative: Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS
2019: HRSA_HIV PrEP Distribtuion-Pre-Exposure Prophylaxis Implementation and Dissemination
2019: HRSA_Strengthening Systems of Care for People Living with HIV and Opioid Use Disorder
2019: NIAID_PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS
2019: NIAID_Preclinical Services for HIV Therapeutics
2019: NIH_Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)
2019: NIH_Innovative Epidemiologic Approaches for Understanding Long-term Health Outcomes of HIV-exposed Uninfected (HEU) Populations (R61/R33 Clinical Trial Not Allowed)
2019: USAID_Building a Scaled Private Sector Network for HIV Treatment in South Africa
2019: USAID_Request for quotation_Ethiopia_USAID/PEPFAR program implementation through Local Partner Initiative (LPI) to achieve HIV epidemic control
2019: USAID_Strategic HIV/AIDS and TB Response Program (SHARP)_FHI 360
2020: CDC-RFA-PS21-2102 Comprehensive High-Impact HIV Prevention Programs for Community-Based Organizations
2020: NIDA_NOIP: Implementing the HIV Service Cascade for Justice-Involved Populations
2021: CDC_Comprehensive High-Impact HIV Prevention Programs for Young Men of Color Who Have Sex with Men and Young Transgender Persons of Color
2021: FY 2021 Ending the HIV Epidemic-Primary Care HIV Prevention (PCHP) Awards
2021: HHS Awards Over $48 Million to Health Centers for Ending the HIV Epidemic in the U.S. Initiative
2021: HHS_OMH_HIV Challenge: Innovative Community Engagement Strategies to Reduce HIV-Related Stigma and Disparities
2021: HRSA_HHS Awards $2.21 Billion in Fiscal Year 2021 to Help Americans Access HIV Care, Support Services, and Medication
2021: NIAID_American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional)
2021: NIAID_Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed)
2021: NIAID_Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)
2021: NIAID_Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)
2021: NIAID_Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61/R33 Clinical Trial Optional)
2021: NIAID_Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)
2021: NIAID_SBIR Contract Solicitation (PHS 2022-1) for Small Businesses
2021: NIDA: PrEP for HIV Prevention among Substance Using Populations (R01
2021: NIMHD_Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)
2021: NINDS_Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)
2021: OMH_HHS Selects Phase 1 Winners of the National Competition to Reduce HIV-Related Stigma and Disparities
2021: USAID_$100,000 Challenge: Innovative Data Methods for Market Segmentation of HIV Services_medium.com
2022: CDC_Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients
2022: Fogarty_HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
2022: Fogarty_Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01)
2022: HRSA_Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Capacity-Building Provider
2022: HRSA_Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration Sites
2022: HRSA_Ryan White HIV/AIDS Program Part D Coordinated HIV Services and Access to Research for Women, Infants, Children, and Youth (WICY) Existing Geographic Service Areas
2022: HRSA_Telehealth Strategies to Maximize HIV Care
2022: NCI_NOIP_Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)
2022: NCI_U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional)
2022: NICHD_Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)
2022: NICHD_Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center (UM2 Clinical Trial Optional)
2022: NICHD_NOIP_Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN) Scientific Leadership Center (UM2 Clinical Trial Required), and Operations and Collaborations Center (UM1 Clinical Trial)
2022: NIDA_Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)
2022: NIDA: Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24
2022: NIH Grant Supports Machine Learning to Improve HIV Patient Outcomes
2022: NIMH_Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)
2022: NIMH_Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)
2022: NIMH_NOIP: Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R01 Clinical Trial Optional)
2022: NIMHD_Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01-Clinical Trial Required)
2023: NHLBI_Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
2023: NIAID_Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)
2023: NIAID_New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed)
2023: NICHD_Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)
2023: NICHD_Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
2023: NIDA_New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional )
2023: NIDA: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)
2023: NIH_NIDCR_NOSI: Basic and Translational Oral Health Research Related to HIV/AIDS
2023: NIMH_AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
2024: NCI_High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
2024: NIAID_NOSI_Harnessing Big Data to Halt HIV
2024: NIAID_NOSI_HIV/AIDS in the Era of COVID-19: When Pandemics Collide
2024: NIDA_Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
2025: NHLBI_NOSI: Examining Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Heart, Lung, Blood, and Sleep Function
2025: NIDA_NOSI_Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use
2025: NIDA_NOSI: Reducing Stigma Related to Drug Use in Human Service Settings
Anti-retroviral Treatment (ART)
Consolidators HIV/AIDS
Dr Eric Goosby, U.N. Special Envoy on Tuberculosis, former, U.S. Global AIDS Coordinator (2021)
Global Fund to Fight AIDS, Tuberculosis & Malaria